Logo

American Heart Association

  21
  0


Final ID: MP1228

ECMO Combined with Thrombectomy Yields Superior Outcomes in Acute High-Risk Pulmonary Embolism

Abstract Body (Do not enter title and authors here): Background:
Extracorporeal membrane oxygenation (ECMO) is used as a rescue therapy in patients with severe high-risk pulmonary embolism (PE), but data on optimal management and especially on mid- and long-term outcomes remain limited.

Hypothesis:
We hypothesized that ECMO combined with thrombectomy would lead to better short- and long-term outcomes than ECMO with thrombolysis or ECMO alone.

Methods:
We retrospectively reviewed the medical records of patients with high-risk PE who received ECMO at a single institution between January 2016 and July 2024. Patients were categorized into three groups based on the type of adjunctive reperfusion therapy received: those who underwent thrombectomy, including surgical and percutaneous mechanical thrombectomy; those who received thrombolysis, including systemic thrombolysis and catheter-directed thrombolysis; and those who were managed with ECMO alone without reperfusion therapy. We compared patient characteristics and clinical outcomes across these groups.

Results:
A total of 72 patients with high-risk PE underwent ECMO during the study period, with a median age of 52.5 years (95% CI: 42.0–65.3). Of these, 22 patients received ECMO with thrombectomy (5 surgical, 17 percutaneous), 28 patients received ECMO with thrombolysis (13 systemic, 15 catheter-directed), and 22 patients received ECMO alone. There were no significant demographic differences among the groups. The incidence of cardiac arrest was similar: ECMO alone (72.7%), thrombolysis (67.9%), and thrombectomy (77.3%) (P=0.76). The median duration of ECMO support was 5 days (95% CI: 4–6 days), with no significant difference among the three groups (P = 0.2). Successful weaning from ECMO was achieved in 100% of the thrombectomy group, 60.7% of the thrombolysis group, and 36.4% of the ECMO-alone group (P<0.01). Survival to hospital discharge was highest in the ECMO with thrombectomy group (81.8%), compared to 57.1% in the thrombolysis group and 18.1% in the ECMO alone group (P<0.01). There were no significant differences in in-hospital complications among the groups. The 1- and 3-year survival rates were 81.8%, and 72.7% in the ECMO with thrombectomy group; 55.7%, and 46.4% in the ECMO with thrombolysis group; and 18.2%, and 18.2% in the ECMO alone group (P <0.001).

Conclusion:
ECMO without reperfusion therapy was associated with poor outcomes, whereas ECMO with thrombectomy provided the best short- and long-term survival, followed by thrombolysis.
  • Fujimoto, Ryo  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Pugliese, Steven  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Bermudez, Christian  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Gregorio, Paulo  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Richards, Tomas  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Olia, Salim  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Mazur, Zane  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Wald, Joyce  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Glassmoyer, Lauren  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Kobayashi, Tai  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Giri, Jay  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Author Disclosures:
    RYO FUJIMOTO: DO NOT have relevant financial relationships | steven pugliese: DO NOT have relevant financial relationships | Christian Bermudez: DO NOT have relevant financial relationships | Paulo Gregorio: No Answer | Tomas Richards: No Answer | Salim Olia: DO have relevant financial relationships ; Consultant:Magenta Medical:Active (exists now) | Zane Mazur: DO NOT have relevant financial relationships | Joyce Wald: No Answer | Lauren Glassmoyer: DO NOT have relevant financial relationships | Tai Kobayashi: DO have relevant financial relationships ; Consultant:Medtronic:Active (exists now) ; Consultant:Endovascular Engineering:Active (exists now) ; Consultant:Sonivie Medical:Active (exists now) ; Consultant:Recor Medical:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Pushing the Limits: ECMO, Impella, and the Science Behind Their Power

Sunday, 11/09/2025 , 09:15AM - 10:15AM

Moderated Digital Poster Session

More abstracts on this topic:
Divergent Transcriptomic Responses in Liver and Colon after ECMO resuscitation in an Infant Piglet Model

Zakrzewski Jack, Mancuso Christopher, Thomson Lindsay, Khailova Ludmila, Lehmann Tanner, Niemiec Sierra, Davidson Jesse

Comparing Outcomes in Low versus High Activated Partial Thromboplastin Time-guided Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation

Khoury Fadi, Ma Mariel, Specht Hayley, Chiang I-hui

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available